The Efficacy and Safety of Additional Treatment with Short-acting Muscarinic Antagonist Combined with Long-acting Beta-2 Agonist in Stable Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis

Overview

Journal Chron Respir Dis

Publisher Sage Publications

Date 2023 Mar 26

PMID 36967224

Authors

Kazuya Tanimura

Susumu Sato

Yukio Fujita

Yoshifumi Yamamoto

Takashi Hajiro

Nobuyuki Horita

Tomotaka Kawayama

Shigeo Muro

Affiliations

Soon will be listed here.

Abstract

Background: The rationale for additional treatment with short-acting bronchodilators combined with long-acting bronchodilators for patients with chronic obstructive pulmonary disease (COPD) is not adequately studied.

Methods: We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of a short-acting muscarinic antagonist (SAMA) therapy combined with a long-acting beta-2 agonist (LABA) in patients with stable COPD. Pulmonary function, dyspnea, health-related quality of life, exercise tolerance, physical activity, exacerbations of COPD, and adverse events during regular use were set as outcomes of interest.

Results: We included five controlled trials including two sets of publicly available online data without article publications for the meta-analysis. Additional use of SAMA plus LABA showed a significant improvement in the peak response in FEV (mean difference (MD) 98.70 mL, < .00001), transitional dyspnea index score (MD .85, = .02), and St George's Respiratory Questionnaire score (MD -2.00, = .008) compared to LABA treatment. There was no significant difference in the risk of exacerbation of COPD ( = .20) and only a slight trend of increased severe adverse events (OR: 2.16, = .08) and cardiovascular events (OR: 2.38, = .06).

Conclusion: Additional treatment with SAMA combined with LABA could be a feasible choice due to its efficacy and safety.

References

Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12):1128-38. DOI: 10.1056/NEJMoa0909883. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

Hirano T, Matsunaga K, Hamada K, Uehara S, Suetake R, Yamaji Y . Combination of assist use of short-acting beta-2 agonists inhalation and guidance based on patient-specific restrictions in daily behavior: Impact on physical activity of Japanese patients with chronic obstructive pulmonary disease. Respir Investig. 2019; 57(2):133-139. DOI: 10.1016/j.resinv.2018.12.001. View

Cazzola M, Matera M, Di Perna E, Califano C, Damato M, Mazzarella G . Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD. Respir Med. 2000; 93(12):909-11. DOI: 10.1016/s0954-6111(99)90058-6. View

Hasegawa M, Dobashi K, Horie T, Wada N, Shirakura K . Influence of inhaled procaterol on pulmonary rehabilitation in chronic obstructive pulmonary disease. Respir Investig. 2012; 50(4):135-9. DOI: 10.1016/j.resinv.2012.08.003. View

Kitaguchi Y, Fujimoto K, Komatsu Y, Hanaoka M, Honda T, Kubo K . Additive efficacy of short-acting bronchodilators on dynamic hyperinflation and exercise tolerance in stable COPD patients treated with long-acting bronchodilators. Respir Med. 2012; 107(3):394-400. DOI: 10.1016/j.rmed.2012.11.013. View

Sichletidis L, Kottakis J, Marcou S, Constantinidis T, Antoniades A . Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. Int J Clin Pract. 2000; 53(3):185-8. View

Stephenson A, Seitz D, Bell C, Gruneir A, Gershon A, Austin P . Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch Intern Med. 2011; 171(10):914-20. DOI: 10.1001/archinternmed.2011.170. View

Waschki B, Kirsten A, Holz O, Muller K, Meyer T, Watz H . Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011; 140(2):331-342. DOI: 10.1378/chest.10-2521. View

10.

van Noord J, Bantje T, Eland M, Korducki L, CORNELISSEN P . A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax. 2000; 55(4):289-94. PMC: 1745719. DOI: 10.1136/thorax.55.4.289. View

11.

Rutten-van Molken M, Roos B, van Noord J . An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax. 1999; 54(11):995-1003. PMC: 1745382. DOI: 10.1136/thx.54.11.995. View

12.

Kerstjens H, Bantje T, Luursema P, Sinninghe Damste H, de Jong J, Lee A . Effects of short-acting bronchodilators added to maintenance tiotropium therapy. Chest. 2007; 132(5):1493-9. DOI: 10.1378/chest.06-3059. View

13.

Miravitlles M, Garcia-Rivero J, Ribera X, Galera J, Garcia A, Palomino R . Exercise capacity and physical activity in COPD patients treated with a LAMA/LABA combination: a systematic review and meta-analysis. Respir Res. 2022; 23(1):347. PMC: 9753337. DOI: 10.1186/s12931-022-02268-3. View

14.

Matera M, Caputi M, Cazzola M . A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Respir Med. 1996; 90(8):497-9. DOI: 10.1016/s0954-6111(96)90178-x. View

15.

Watz H, Waschki B, Meyer T, Magnussen H . Physical activity in patients with COPD. Eur Respir J. 2008; 33(2):262-72. DOI: 10.1183/09031936.00024608. View

16.

Appleton S, Jones T, Poole P, Pilotto L, Adams R, Lasserson T . Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006; (3):CD006101. PMC: 7200053. DOI: 10.1002/14651858.CD006101. View

17.

van Geffen W, Carpaij O, Westbroek L, Seigers D, Niemeijer A, Vonk J . Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial. Respir Med. 2020; 171:106064. DOI: 10.1016/j.rmed.2020.106064. View

18.

Decramer M, Chapman K, Dahl R, Frith P, Devouassoux G, Fritscher C . Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2014; 1(7):524-33. DOI: 10.1016/S2213-2600(13)70158-9. View

19.

van Noord J, de Munck D, Bantje T, Hop W, Akveld M, Bommer A . Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J. 2000; 15(5):878-85. DOI: 10.1034/j.1399-3003.2000.15e11.x. View

20.

Miravitlles M, Soler-Cataluna J, Calle M, Molina J, Almagro P, Quintano J . Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. Arch Bronconeumol. 2017; 53(6):324-335. DOI: 10.1016/j.arbres.2017.03.018. View